10 news items
Rhythm Pharmaceuticals Presents Data From Phase 3 Pediatrics Trial At Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
""Efficacy in Weight Reduction and Safety in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway–Related Obesity Treated With a Therapy for 12 Months"
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
""Efficacy in Weight Reduction and Safety in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway–Related Obesity
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, and no new safety concerns were observed during the long-term extension trial.In January 2024, Rhythm announced the completion of screening
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, no AEs that led to study discontinuation during the trial, and no new safety concerns were observed during the long-term extension trial
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety Information
o2n9 qkap
RYTM
16 Apr 24
on reporting suspected adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety
marunv02saqnuu6wr06zn1drn0ywmah4kba
RYTM
25 Mar 24
- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential
ihmpu09pa9o9l1pcfr2rlgsbp94bqplcbj
RYTM
11 Mar 24
for additional Important Safety Information. Forward-looking Statements This press release contains forward
ola 1c2vnhjd5c2zq3antldumqggx3jf1suu
RYTM
6 Mar 24
. Please see the full Prescribing Information for additional Important Safety Information. Forward-looking Statements
jovgz4exkh7s52qvtmrsle0vyo5d30pfmqfyi61oyy3d3sohb2ci3tx
RYTM
22 Feb 24
Safety Information. Forward-looking Statements This press release contains forward-looking statements within
- Prev
- 1
- Next